We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

FGFR

Fibroblast growth factor receptor (FGFR) inhibitors act on FGFR1 to FGFR4, four receptor tyrosine kinases. FGFR signaling controls cell proliferation, migration and differentiation in development and angiogenesis. Amplifications, activating mutations and gene fusions of FGFR genes have been found in many tumor types. PD173074 was crystallized with the FGFR1 kinase domain in 1998, which showed how it occupies the adenosine triphosphate (ATP) pocket. Infigratinib and fexagratinib are FGFR-focused inhibitors used to study cells that depend on FGFR signaling. Nintedanib and pazopanib HCl inhibit FGFR together with vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). Kinases outside the FGFR family are covered by sibling categories such as VEGFR and PDGFR.

4 Items

  • 2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose
    Cat. No.
    A33462
    CAS No.
    150302-84-4

    2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose

    2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose functions as a selective binder for Fibroblast Growth Factor Receptor 3 (FGFR3) and BRAF, playing a pivotal role in modulating pathways associated with cancer progression. Derived from Atractylodes japonica, this compound exhibits low cytotoxicity towards cancer cell lines, making it a suitable candidate for research applications focused on targeted cancer therapies and signaling pathway studies. Its unique structural characteristics enhance its potential for further exploration in drug development and therapeutic interventions.

    In stock View Details
    5 mg
    $605.00
    All 1 sizes
  • FGFR-IN-3
    Cat. No.
    A33529
    CAS No.
    2488762-63-4

    FGFR-IN-3

    FGFR-IN-3 is a potent modulator of fibroblast growth factor receptors (FGFR) with demonstrated oral bioavailability and blood-brain barrier penetration. This compound exhibits neuroprotective properties, making it a valuable tool in research related to neurodegenerative diseases. FGFR-IN-3's ability to influence FGFR signaling pathways supports its potential in understanding and developing treatments for various neurological conditions.

    In stock View Details
    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • SUN13837
    Cat. No.
    A33551
    CAS No.
    1080650-67-4

    SUN13837

    SUN13837 is a potent orally active modulator of fibroblast growth factor receptors (FGFRs) with the ability to penetrate the blood-brain barrier. It exhibits neuroprotective properties, making it relevant for research in neurodegenerative diseases. This compound can serve as a valuable tool for investigating therapeutic interventions in FGFR-related neurological conditions.

    In stock View Details
    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • FGFR-IN-7
    Cat. No.
    A33572
    CAS No.
    2488764-17-4

    FGFR-IN-7

    FGFR-IN-7 is a potent fibroblast growth factor receptor modulator with oral bioavailability and effective blood-brain barrier penetration. It exhibits neuroprotective activity, making it a valuable tool for studying neurodegenerative diseases. Its ability to enhance brain exposure while reducing the risk of phospholipidosis emphasizes its potential in therapeutic applications related to CNS disorders.

    In stock View Details
    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

4 Items

Added to your cart

View Cart Checkout

    Loading...